Japan Trend Of Concurrent Trials Leads ICON To Triple Japan Staff
This article was originally published in PharmAsia News
A Japan drug maker trend toward concurrent trials of drugs has led Ireland-based ICON to triple its Japanese workforce over the next three years
You may also be interested in...
Per- and polyfluoroalkyl substances (PFAS) are under increasing scrutiny in the US and Europe. Stakeholders have until 31 July to submit information to the authorities of five European countries as they prepare a joint proposal for a broad PFAS restriction under the bloc’s REACH regulation.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.